Flexion Therapeutics Inc (NASDAQ:FLXN) was the target of unusually large options trading activity on Monday. Investors purchased 3,373 call options on the stock. This represents an increase of approximately 675% compared to the typical daily volume of 435 call options.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $44.00 price target on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of Flexion Therapeutics in a research note on Sunday, September 17th. Finally, Northland Securities reiterated a “buy” rating and set a $40.00 price target on shares of Flexion Therapeutics in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $98.33.

Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at $25.66 on Friday. Flexion Therapeutics has a 52 week low of $16.17 and a 52 week high of $32.25. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87.

In related news, insider Michael D. Clayman acquired 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares in the company, valued at approximately $835,322. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Neil Bodick acquired 2,700 shares of the stock in a transaction dated Tuesday, November 21st. The stock was bought at an average price of $24.49 per share, for a total transaction of $66,123.00. Following the purchase, the insider now owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 8,700 shares of company stock worth $208,323. 15.98% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Bank of New York Mellon Corp boosted its stake in Flexion Therapeutics by 27.9% during the second quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after buying an additional 591,981 shares in the last quarter. State Street Corp boosted its stake in shares of Flexion Therapeutics by 66.3% in the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after purchasing an additional 549,948 shares in the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after purchasing an additional 376,745 shares in the last quarter. Nexthera Capital LP acquired a new stake in shares of Flexion Therapeutics in the 2nd quarter valued at $4,661,000. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Flexion Therapeutics by 73.7% in the 2nd quarter. Pictet Asset Management Ltd. now owns 472,796 shares of the specialty pharmaceutical company’s stock valued at $8,080,000 after purchasing an additional 200,657 shares in the last quarter. Hedge funds and other institutional investors own 72.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/02/traders-buy-large-volume-of-flexion-therapeutics-call-options-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Stock Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related stocks with our FREE daily email newsletter.